专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5182097A Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content 失效
标题翻译：用减少或无氯代内容的计量剂量吸入剂输送药物的配方
公开(公告)号：US5182097A
公开(公告)日：1993-01-26
申请号：US655668
申请日：1991-02-14
申请人： Peter R. Byron , Richard N. Dalby
发明人： Peter R. Byron , Richard N. Dalby
IPC分类号： A61K9/00 , A61K9/12 , A61K31/135 , C07C19/08
CPC分类号： A61K9/008 , A61K9/124 , Y10S514/97
摘要： Aerosol formulations for use in metered dose inhalers are disclosed which include 1,1,1,2-tetrafluoroethane alone and in combination with other compounds as well as various hydrocarbon blends. The density, vapor pressure, flame extension characteristics, dispersability of medicant, dissolvability of surfactant, respirable fraction, and compatibility elastomer seals for the aerosol formulations have been examined. The aerosol formulations are attractive alternatives to chlorofluorocarbon based aerosols since they do not deplete the ozone layer.
摘要翻译：公开了用于计量剂量吸入器的气溶胶制剂，其包括单独的1,1,1,2-四氟乙烷和与其它化合物以及各种烃共混物组合的气溶胶制剂。已经研究了密度，蒸汽压力，火焰延伸特性，药物的分散性，表面活性剂的可溶性，可呼吸部分和气溶胶配方的相容性弹性体密封。气溶胶配方是含氟氯烃气溶胶的有吸引力的替代品，因为它们不会消耗臭氧层。

2. 发明授权

US5190029A Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content 失效
标题翻译：通过减少或不降低含氯氟碳含量的计量吸入器输送药物的配方
公开(公告)号：US5190029A
公开(公告)日：1993-03-02
申请号：US721698
申请日：1991-06-26
申请人： Peter R. Byron , Richard N. Dalby
发明人： Peter R. Byron , Richard N. Dalby
IPC分类号： A61K9/00 , A61K9/12 , A61M11/00 , C09K3/30
CPC分类号： A61K9/008
摘要： Aerosol formulations for use in metered dose inhalers are disclosed which include 1,1,1,2-tetrafluoroethane alone and in combination with other compounds as well as various hydrocarbon blends. The density, vapor pressure, flame extension characteristics, dispersability of medicant, dissolvability of surfactant, respirable fraction, and compatibility elastomer seals for the aerosol formulations have been examined. The aerosol formulations are attractive alternatives to chlorofluorocarbon based aerosols since they do not deplete the ozone layer.
摘要翻译：公开了用于计量剂量吸入器的气溶胶制剂，其包括单独的1,1,1,2-四氟乙烷和与其它化合物以及各种烃共混物组合的气溶胶制剂。已经研究了密度，蒸汽压力，火焰延伸特性，药物的分散性，表面活性剂的可溶性，可呼吸部分和气溶胶配方的相容性弹性体密封。气溶胶配方是含氟氯烃气溶胶的有吸引力的替代品，因为它们不会消耗臭氧层。

3. 发明申请

US20110318277A1 TACROLIMUS COMPOSITIONS FOR AEROSOL ADMINISTRATION 审中-公开
标题翻译：用于气溶胶管理的TACROLIMUS组合物
公开(公告)号：US20110318277A1
公开(公告)日：2011-12-29
申请号：US13168856
申请日：2011-06-24
申请人： Richard N. Dalby , Ralph Niven
发明人： Richard N. Dalby , Ralph Niven
IPC分类号： A61K9/12 , A61P37/06
CPC分类号： A61K31/436 , A61K9/008
摘要： The present disclosure relates generally to highly concentrated macrolide solutions for aerosol administration, and related methods of producing and administering the same. In one aspect, provided herein is a receptacle containing a highly concentrated solution of a macrolide compound such as tacrolimus, where the solution exhibits long-term stability in a pMDI canister and achieves high respirable fractions when actuated, among, other features. In yet another aspect, provided is a composition suitable for aerosol administration comprising tacrolimus dissolved in an ethanol-liquified propellant mixture, characterized by a tacrolimus concentration of greater than 0.15 weight percent (w/w) and comprising no more than about 10 weight percent (w/w) ethanol.
摘要翻译：本公开一般涉及用于气雾剂给药的高度浓缩的大环内酯溶液及其相关的生产和施用方法。在一个方面，本文提供的是含有大环内酯类化合物如他克莫司的高度浓缩溶液的容器，其中溶液在pMDI罐中表现出长期稳定性，并且在致动时实现高呼吸成分，以及其它特征。在另一方面，提供了适用于气溶胶施用的组合物，其包含溶解在乙醇液化的推进剂混合物中的他克莫司，其特征在于他克莫司浓度大于0.15重量％（w / w），并且包含不超过约10重量％ w / w）乙醇。

4. 发明授权

US5202110A Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants 失效
标题翻译：通过不含氯氟烃推进剂的计量吸入器输送二丙酸倍氯米松的配方
公开(公告)号：US5202110A
公开(公告)日：1993-04-13
申请号：US824030
申请日：1992-01-22
申请人： Richard N. Dalby , Peter R. Byron
发明人： Richard N. Dalby , Peter R. Byron
IPC分类号： A61K9/00 , A61K9/12 , A61K31/57 , A61K31/573 , A61K47/48
CPC分类号： A61K9/008 , A61K31/57 , A61K9/124
摘要： Beclomethasone diproprionate (BDP) forms a clathrate with HCFC-123, dimethyl ether (DME) and HCFC-141b which are less harmful propellants than the CFC propellants currently used in metered dose inhalers (MDIs). The clathrate can be remicronized and suspended for use in an MDI. BDP also is completely dissolved by DME based propellant blends and certain HCFC 123 propellant blends. Using propellant blends which completely dissolve BDP will assure more efficient dosing with an MDI.
摘要翻译：二氯丙酸倍氯米松（BDP）与HCFC-123，二甲醚（DME）和HCFC-141b形成包合物，其比目前用于计量吸入器（MDIs）的CFC推进剂更不利于推进剂。包合物可以被称重并悬浮在MDI中。 BDP也被基于DME的推进剂混合物和某些HCFC 123推进剂混合物完全溶解。使用完全溶解BDP的推进剂混合物将确保更有效地配合MDI。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式